Two multicentre, randomised phase III trials evaluated the safety and efficacy of the addition of bevacizumab to carboplatin and paclitaxel compared with the chemotherapy regimen alone in patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. The primary endpoint in both trials was progression-free survival (PFS).
The double-blind, placebo-controlled study GOG-0218 involved 1,873 previously untreated women, who received bevacizumab 15mg/kg every 3 weeks for up to 15 months. Patients who received bevacizumab throughout their chemotherapy treatment experienced 18.2 months of PFS, compared with 12 months for patients who received standard chemotherapy plus a placebo (HR=0.62 [95% CI, 0.52-0.75]; p<0.0001).
The two-arm, open-label ICON7 study involved 1,528 women with early stage and advanced disease and used a lower dose for a shorter duration of bevacizumab (7.5mg/kg every 3 weeks for up to 12 months). Median PFS was 16.9 months with standard therapy and 19.3 months with standard therapy plus bevacizumab (HR=0.86 [95% CI, 0.75-0.98]; p=0.001).
Bevacizumab is currently used for treating advanced breast cancer, colorectal cancer, non-small cell lung cancer and renal cancer.
View Avastin drug record
Further Information: Roche Products Ltd